نتائج البحث - "Zvonko, Milicevic"

1

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

المؤلفون: Tim, Heise, Andrea, Mari, J Hans, DeVries, Shweta, Urva, Jing, Li, Edward John, Pratt, Tamer, Coskun, Melissa K, Thomas, Kieren J, Mather, Axel, Haupt, Zvonko, Milicevic

المساهمون: General Internal Medicine, APH - Health Behaviors & Chronic Diseases, Amsterdam Gastroenterology Endocrinology Metabolism

المصدر: Lancet. Diabetes and endocrinology, 10(6), 418-429. Elsevier BV

مصطلحات موضوعية: Adult, Blood Glucose, Glycated Hemoglobin, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Insulins, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide-1 Receptor, Islets of Langerhans, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, Double-Blind Method, Internal Medicine, Humans, Hypoglycemic Agents, Insulin Resistance

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114333746341eaa7eb406318786f093dTest
https://pure.amc.nl/en/publications/effects-of-subcutaneous-tirzepatide-versus-placebo-or-semaglutide-on-pancreatic-islet-function-and-insulin-sensitivity-in-adults-with-type-2-diabetesTest(7eebb311-02b1-40db-b66f-d99628ecb9b1).html

2

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

المؤلفون: Ross Bray, Amir Nikooienejad, Deborah A. Robins, Axel Haupt, Kevin L. Duffin, Jonathan M. Wilson, Melissa K. Thomas, Zvonko Milicevic, Xuewei Cui

المصدر: The Journal of Clinical Endocrinology and Metabolism

مصطلحات موضوعية: Blood Glucose, Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Clinical Biochemistry, Type 2 diabetes, Biochemistry, Endocrinology, Insulin-Secreting Cells, Medicine, Proinsulin, GIP, Middle Aged, Prognosis, Homeostatic model assessment, Female, type 2 diabetes, AcademicSubjects/MED00250, medicine.drug, Adult, medicine.medical_specialty, Adolescent, tirzepatide, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 Receptor, Young Adult, Insulin resistance, Clinical Trials, Phase II as Topic, Internal medicine, insulin sensitivity, Humans, Hypoglycemic Agents, Glucagon-like peptide 1 receptor, Clinical Research Articles, Aged, Glycated Hemoglobin, Adiponectin, business.industry, beta-cell function, Insulin, Biochemistry (medical), medicine.disease, Diabetes Mellitus, Type 2, Dulaglutide, Insulin Resistance, business, GLP-1, Biomarkers, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6320a46b48d64dfafd5061c85da73165Test
http://europepmc.org/articles/PMC7823251Test

3

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

المؤلفون: Axel Haupt, Xuewei Cui, Michael A. Nauck, Shweta Urva, Joanna Van, Zvonko Milicevic, Deborah A. Robins, Ross Bray, Juan P. Frias, Charles Benson

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Male, medicine.medical_specialty, Side effect, Nausea, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Placebo-controlled study, 030209 endocrinology & metabolism, Gastric Inhibitory Polypeptide, glucagon‐like peptide‐1 analogue, Type 2 diabetes, glucose‐dependent insulinotropic peptide, 030204 cardiovascular system & hematology, Placebo, Gastroenterology, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Double-Blind Method, Internal medicine, randomized trial, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Adverse effect, Glucagon-like peptide 1 receptor, Aged, Glycated Hemoglobin, antidiabetic drug, business.industry, Original Articles, Middle Aged, medicine.disease, Treatment Outcome, Diabetes Mellitus, Type 2, Tolerability, Original Article, incretin therapy, type 2 diabetes, medicine.symptom, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785f264f865d5ea0bf77cdf9ec989aa6Test
https://doi.org/10.1111/dom.13979Test

4

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial

المؤلفون: Zvonko Milicevic, Francesco Giorgino, Luis-Emilio Garcia-Perez, Maria Yu, Axel Haupt

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Agonist, Blood Glucose, Male, medicine.medical_specialty, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Recombinant Fusion Proteins, Glucagon-Like Peptides, Insulin Glargine, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Glucagon, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Post-hoc analysis, dulaglutide, Weight Loss, Internal Medicine, Medicine, Humans, Hypoglycemic Agents, basal insulin, Aged, Glycated Hemoglobin, business.industry, Insulin glargine, Brief Report, Middle Aged, medicine.disease, Postprandial Period, Immunoglobulin Fc Fragments, Clinical trial, Postprandial, Diabetes Mellitus, Type 2, Dulaglutide, Brief Reports, Female, sense organs, type 2 diabetes, business, GLP‐1, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bec5936ad72f840f15dced712c732323Test
http://europepmc.org/articles/PMC6852007Test

5

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

المؤلفون: Lai S. Tham, Ying G. Li, Dagmar Bartaskova, Zvonko Milicevic, Brad Woodward, David A. Cox, Juan P. Frias, Alan G. Wynne, Beata Matyjaszek-Matuszek

المصدر: Diabetes, Obesity and Metabolism. 21:2048-2057

مصطلحات موضوعية: Adult, Blood Glucose, Male, medicine.medical_specialty, Nausea, Recombinant Fusion Proteins, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Urology, Placebo-controlled study, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, 03 medical and health sciences, Subcutaneous injection, 0302 clinical medicine, Endocrinology, Double-Blind Method, Weight loss, Weight Loss, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Aged, Glycated Hemoglobin, business.industry, Middle Aged, medicine.disease, Metformin, Immunoglobulin Fc Fragments, Treatment Outcome, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Dulaglutide, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbb56e6e05c0c6bbde72032bfb9c14cTest
https://doi.org/10.1111/dom.13764Test

6

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

المؤلفون: Zhuoxin Yu, Luis Nevárez Ruiz, M. Angelyn Bethel, Raleigh E. Malik, Zvonko Milicevic, Enzo Bonora, Ying G. Li, Juan P. Frias, David A. Cox

المصدر: Diabetes Care

مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Recombinant Fusion Proteins, Urology, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, Body weight, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Diabetes mellitus, dulaglutide, Internal Medicine, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, Advanced and Specialized Nursing, Glycated Hemoglobin, Emerging Therapies: Drugs and Regimens, business.industry, medicine.disease, Rescue medication, Metformin, Discontinuation, Immunoglobulin Fc Fragments, Treatment Outcome, Diabetes Mellitus, Type 2, Dulaglutide, Drug Therapy, Combination, type 2 diabetes, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad7a41393f7cc0eed8d6c9ebabee323Test
https://pubmed.ncbi.nlm.nih.gov/33397768Test

7

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

المؤلفون: Shweta Urva, Ruth E. Gimeno, Mark E Kutner, Michael A. Nauck, Axel Haupt, Joanna Van, Zvonko Milicevic, Charles Benson, Juan P. Frias, Deborah A. Robins, Xuewei Cui

المصدر: Lancet (London, England). 392(10160)

مصطلحات موضوعية: 0301 basic medicine, Blood Glucose, Male, medicine.medical_specialty, Recombinant Fusion Proteins, Population, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, Gastric Inhibitory Polypeptide, Placebo, Gastroenterology, Drug Administration Schedule, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Weight loss, Internal medicine, Diabetes mellitus, Weight Loss, medicine, Humans, Hypoglycemic Agents, education, Glycated Hemoglobin, education.field_of_study, business.industry, General Medicine, Middle Aged, medicine.disease, Metformin, Immunoglobulin Fc Fragments, 030104 developmental biology, Treatment Outcome, Tolerability, Diabetes Mellitus, Type 2, Dulaglutide, Female, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010e846962f8f8c5b018a7f53d736ddeTest
https://pubmed.ncbi.nlm.nih.gov/30377302Test

8

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

المؤلفون: Robert J. Konrad, Kenneth F. Mace, Greg Anglin, Wolfgang Glaesner, Zachary Skrivanek, Kristine D. Harper, Zvonko Milicevic, Chrisanthi A. Karanikas

المصدر: Diabetes, Obesity and Metabolism. 18:533-536

مصطلحات موضوعية: Risk, Agonist, medicine.drug_class, Injections, Subcutaneous, Recombinant Fusion Proteins, Endocrinology, Diabetes and Metabolism, Population, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, Cross Reactions, 030204 cardiovascular system & hematology, Pharmacology, Placebo, Severity of Illness Index, Drug Administration Schedule, Glucagon-Like Peptide-1 Receptor, Drug Hypersensitivity, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, education, Adverse effect, Glucagon-like peptide 1 receptor, education.field_of_study, Dose-Response Relationship, Drug, business.industry, Incidence, Solid Phase Extraction, Drugs, Investigational, Middle Aged, medicine.disease, Antibodies, Neutralizing, Hypoglycemia, Immunoglobulin Fc Fragments, Diabetes Mellitus, Type 2, Hyperglycemia, Dulaglutide, Drug Eruptions, business, Exenatide, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a153a018dd6df27d209e66c4e459ff9dTest
https://doi.org/10.1111/dom.12640Test

9

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

المؤلفون: Francisco J. Tinahones, Juan P. Frias, Honghua Jiang, Luis-Emilio Garcia-Perez, Zvonko Milicevic, Julio Wainstein, D. Bradley Woodward, Kenneth E. Robertson, Bernhard Ludvik

المصدر: The lancet. Diabetesendocrinology. 6(5)

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Recombinant Fusion Proteins, Population, Placebo-controlled study, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, education, Sodium-Glucose Transporter 2 Inhibitors, Glycated Hemoglobin, education.field_of_study, business.industry, Middle Aged, medicine.disease, Metformin, Immunoglobulin Fc Fragments, Treatment Outcome, Tolerability, Diabetes Mellitus, Type 2, Dulaglutide, Drug Therapy, Combination, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98bc6b8a2e50aeaa553a9cad2fcb51dfTest
https://pubmed.ncbi.nlm.nih.gov/29803266Test

10

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

المؤلفون: Lawrence Blonde, Honghua Jiang, Jessie L. Fahrbach, Zvonko Milicevic, Jorge Luiz Gross, Vincent Woo, Johan Jendle

المصدر: The Lancet. 385:2057-2066

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, Recombinant Fusion Proteins, medicine.medical_treatment, Glucagon-Like Peptides, Insulin Glargine, Type 2 diabetes, Bedtime, Drug Administration Schedule, law.invention, Young Adult, Randomized controlled trial, law, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Aged, Glycated Hemoglobin, Insulin Lispro, Intention-to-treat analysis, Insulin glargine, business.industry, Insulin, General Medicine, Middle Aged, Postprandial Period, medicine.disease, Immunoglobulin Fc Fragments, Surgery, Insulin, Long-Acting, Treatment Outcome, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Dulaglutide, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db9ae694e7f70fa658ac922998e28665Test
https://doi.org/10.1016/s0140-6736Test(15)60936-9

تنقيح النتائج